These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 28569569

  • 1. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
    Tacconelli S, Bruno A, Grande R, Ballerini P, Patrignani P.
    Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
    [Abstract] [Full Text] [Related]

  • 2. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S.
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [Abstract] [Full Text] [Related]

  • 3. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 4. Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned?
    Minhas D, Nidhaan A, Husni ME.
    Rheum Dis Clin North Am; 2023 Feb; 49(1):179-191. PubMed ID: 36424024
    [Abstract] [Full Text] [Related]

  • 5. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M, Ruschitzka F.
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [Abstract] [Full Text] [Related]

  • 6. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
    Martelli A, Testai L, Anzini M, Cappelli A, Di Capua A, Biava M, Poce G, Consalvi S, Giordani A, Caselli G, Rovati L, Ghelardini C, Patrignani P, Sautebin L, Breschi MC, Calderone V.
    Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
    [Abstract] [Full Text] [Related]

  • 7. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A, Tacconelli S, Patrignani P.
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [Abstract] [Full Text] [Related]

  • 8. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 9. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
    Fiorucci S, Distrutti E.
    Curr Med Chem; 2011 Dec; 18(23):3494-505. PubMed ID: 21756233
    [Abstract] [Full Text] [Related]

  • 10. Anti-inflammatory drugs in the 21st century.
    Rainsford KD.
    Subcell Biochem; 2007 Dec; 42():3-27. PubMed ID: 17612044
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs.
    Patrono C.
    Curr Cardiol Rep; 2016 Mar; 18(3):25. PubMed ID: 26841787
    [Abstract] [Full Text] [Related]

  • 12. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L, White WB, Rostom A, Hochberg M.
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ, Islam K.
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [Abstract] [Full Text] [Related]

  • 14. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.
    Thomas D, Ali Z, Zachariah S, Sundararaj KGS, Van Cuyk M, Cooper JC.
    Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025
    [Abstract] [Full Text] [Related]

  • 15. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
    Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ.
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M, Chowienczyk P, Kirkham B.
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular risk, hypertension, and NSAIDs.
    White WB.
    Curr Rheumatol Rep; 2007 Apr; 9(1):36-43. PubMed ID: 17437665
    [Abstract] [Full Text] [Related]

  • 19. The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.
    Cairns JA.
    Can J Cardiol; 2007 Feb; 23(2):125-31. PubMed ID: 17311118
    [Abstract] [Full Text] [Related]

  • 20. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.